ID: hyp-SDA-2026-04-08-gap-debate-20260406-0
Hypothesis
Temporal Cytokine Receptor Modulation
Time-restricted antagonism of inflammatory cytokine receptors (IL-1R, TNFR) during peak inflammatory phases to break positive feedback loops maintaining microglial priming.
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Time-restricted antagonism of inflammatory cytokine receptors (IL-1R, TNFR) during peak inflammatory phases to break positive feedback loops maintaining microglial priming
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Neurodegeneration Triggers<br/>Amyloid Tau Aggregates"]
B["DAM Microglial Activation<br/>Peak Inflammatory Phase"]
C["IL-1beta TNF-alpha Release<br/>Cytokine Positive Feedback Loop"]
D["IL-1R1 IL1R1 Signaling<br/>MyD88 NF-kappaB Activation"]
E["TNFRSF1A TNFR1 Signaling<br/>Inflammatory Gene Program"]
F["Microglial Priming Maintained<br/>Sustained Neuroinflammation"]
G["Time-Restricted IL1R TNFR Antagonism<br/>Breaks Positive Feedback"]
H["Homeostatic Microglial State Restored<br/>Inflammation Resolved"]
A --> B
B --> C
C --> D
C --> E
D --> F
E --> F
F -.->|"broken by"| G
G --> H
style F fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports3 contradicts
Supports
Myocardial infarction augments sleep to limit cardiac inflammation and damage.
Supports
The alarmin interleukin-1α triggers secondary degeneration through reactive astrocytes and endothelium after spinal cord injury.
Supports
Acute sleep deprivation exacerbates systemic inflammation and psychiatry disorders through gut microbiota dysbiosis and disruption of circadian rhythms.
Supports
Integrated Bioinformatics-Based Identification and Validation of Neuroinflammation-Related Hub Genes in Primary Open-Angle Glaucoma.
Supports
Chronic kidney disease leads to microglial potassium efflux and inflammasome activation in the brain.
Contradicts
Emerging functions and therapeutic targets of IL-38 in central nervous system diseases.
Contradicts
IL-1 receptor 2 (IL-1R2) and its role in immune regulation.
Contradicts
Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — IL1R1
No curated PDB or AlphaFold mapping for IL1R1 yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for IL1R1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0535
Events (7d)
0
Price History
▲6.0%💾 Resource Usage
LLM Tokens
10,654
$0.0639
Total Cost
$0.0639
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF IL1R1/TNFRSF1A antagonists are administered during pharmacokinetically-defined peak inflammatory phases (detected by rising IL-6 plasma levels) rather than at baseline or chronic phases, THEN micro | Microglial priming scores will decrease by >40% (CD68 mean fluorescent intensity normalized to Iba1) in the time-restricted antagonist group compared to vehicle | — no observation — | pending | 0.72 |
| IF IL1R1 is selectively antagonized during verified peak inflammatory phases while TNFRSF1A signaling remains intact (and vice versa), THEN single-receptor blockade during peak inflammation will parti | Dual-receptor peak-phase blockade will reduce Trem2-positive primed microglia frequency by >50% and lower Nlrp3 inflammasome活化 (caspase-1 activity assay, ASC sp | — no observation — | pending | 0.68 |
🔮 Falsifiable Predictions (2)
pendingconf 72%
IF IL1R1/TNFRSF1A antagonists are administered during pharmacokinetically-defined peak inflammatory phases (detected by rising IL-6 plasma levels) rather than at baseline or chronic phases, THEN microglial priming markers (CD68+, Iba1+, CD86+ cells, qPCR of Cxcl10, Ccl2) will be significantly reduce
Predicted outcome: Microglial priming scores will decrease by >40% (CD68 mean fluorescent intensity normalized to Iba1) in the time-restricted antagonist group compared
Falsification: If microglial priming markers remain elevated (difference <20% from vehicle) OR if equivalent reduction is observed when antagonists are administered during non-peak (trough) inflammatory phases, the
pendingconf 68%
IF IL1R1 is selectively antagonized during verified peak inflammatory phases while TNFRSF1A signaling remains intact (and vice versa), THEN single-receptor blockade during peak inflammation will partially reduce microglial priming while dual-receptor blockade during peak phases will produce synergis
Predicted outcome: Dual-receptor peak-phase blockade will reduce Trem2-positive primed microglia frequency by >50% and lower Nlrp3 inflammasome活化 (caspase-1 activity ass
Falsification: If single-receptor blockade produces equivalent (>80%) priming reduction as dual blockade, this would indicate non-redundancy and suggest the hypothesis overstates the combined importance of both rece
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.